- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 02.06. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.05. | OSR Holdings to acquire VXM01 IP portfolio for $30 million | 2 | Investing.com | ||
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 27.05. | OSR Holdings, Inc.: OSR Holdings Acquires Full VXM01 Intellectual Property Portfolio in $30 Million Transaction | 452 | ACCESS Newswire | Transaction Centralizes VXM01 Ownership and Long-Term Royalty Economics at the OSRH Parent Level BELLEVUE, WA / ACCESS Newswire / May 27, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare... ► Artikel lesen | |
| 13.05. | OSR Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.05. | OSR Holdings rules out reverse stock split amid Nasdaq compliance efforts | 3 | Investing.com | ||
| 12.05. | OSR Holdings, Inc.: CEO Statement to Shareholders | 358 | ACCESS Newswire | A Clear Commitment: No Reverse Stock Split BELLEVUE, WA / ACCESS Newswire / May 12, 2026 / As many of our shareholders are aware, OSR Holdings filed its Preliminary Proxy Statement on Schedule PRE 14A... ► Artikel lesen | |
| 05.05. | OSR Holdings, Inc.: Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target | 517 | ACCESS Newswire | NEW YORK, NY / ACCESS Newswire / May 5, 2026 / Emerging Growth Research today issued a flash report on OSR Holdings, Inc. (Nasdaq:OSRH), reaffirming its Buy-Emerging rating and 12-month price target... ► Artikel lesen | |
| 30.04. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.04. | OSR Holdings, Inc.: OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 | 466 | ACCESS Newswire | OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding... ► Artikel lesen | |
| 30.04. | OSR Holdings Stock Surges Over 41% After Hours: Why Is It Moving? | 4 | Benzinga.com | ||
| 30.04. | OSR Holdings Executes $815 Million Global License Agreement For VXM01 With BCM Europe | 8 | pulse2.com | ||
| 29.04. | OSR Holdings licenses VXM01 to BCME for up to $815M in milestones | 5 | Investing.com | ||
| 29.04. | OSR Holdings, Inc.: OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe | 515 | ACCESS Newswire | Largest shareholder pledges entire equity stake as collateral for milestone obligations, reinforcing alignment with public shareholders BELLEVUE, WA / ACCESS Newswire / April 29, 2026 / OSR Holdings... ► Artikel lesen | |
| 22.04. | Yeiseok Kim wird neuer Chief Operating Officer bei OSR Holdings | - | Investing.com Deutsch | ||
| 22.04. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.04. | OSR Holdings, Inc.: OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note | 397 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / April 9, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH) ("OSR Holdings" or the "Company") today announced a strategic transaction for capital structure optimization with White... ► Artikel lesen | |
| 02.04. | OSR Holdings und BCM Europe: Neue Lizenzvereinbarung für VXM01 sichert Zahlungen von bis zu 815 Mio. $ | 3 | Investing.com Deutsch | ||
| 02.04. | OSR Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | OSR Holdings, Inc. - 10-K, Annual Report | - | SEC Filings |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,170 | +2,90 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,626 | +1,12 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | United Immunity Acquires Macrophage Assets from Carisma Therapeutics | ||
| CAPRICOR | 22,110 | 0,00 % | CAPRICOR THERAPEUTICS, INC. - 8-K, Current Report | ||
| CORMEDIX | 7,560 | +0,13 % | CorMedix, Inc.: U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin Patent Litigation | PARSIPPANY, N.J., June 08, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that the United States Court of Appeals for the Federal Circuit has affirmed the judgment of... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,978 | +2,16 % | Minerva Neurosciences, Inc: Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs | Distinguished panel of experts in psychiatry and neuroscience appointed to guide Phase 3 confirmatory trial of roluperidone and broader R&D strategyBURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| REPLIMUNE | 7,432 | -3,10 % | Replimune Group, Inc.: Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,183 | -2,35 % | Valerio Therapeutics Announces Binding Term-Sheet for Collaboration and Exclusive License With Seed-Stage Biotech Company | Binding term-sheet for a potential aggregate amount of up to USD 200 million and tiered royalties
Regulatory News:
Valerio Therapeutics (FR0010095596 ALVIO), a biotechnology company specializing... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,760 | +0,01 % | Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition | - Continued advancement of the ongoing Phase 1 study of RT-114 via RaniPill® for the treatment of obesity in collaboration with ProGen - - Appointed Alireza Javadi, Ph.D. as Chief Technical Officer... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | NSE - IO Biotech, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ALTO NEUROSCIENCE | 21,510 | 0,00 % | Alto Neuroscience, Inc.: Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression | - Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies - - Trial design and MADRS primary endpoint... ► Artikel lesen | |
| CERO THERAPEUTICS | 0,095 | +0,11 % | CERo Therapeutics Holdings, Inc.: CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial | Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 88,33 | 0,00 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 46,130 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| QIAGEN | 31,980 | -0,28 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen |
Das Unternehmen OSR HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,02 % bei einem Aktienkurs von 0,385 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.